Synaptic changes in dementia: links to cognition and behaviour

Size: px
Start display at page:

Download "Synaptic changes in dementia: links to cognition and behaviour"

Transcription

1 Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research

2 Agenda Discuss synaptic changes in various dementias Alzheimer s disease (AD) most common dementia 50-60% of all cases Vascular dementia % Lewy body dementia (Dementia with Lewy bodies & Parkinson s disease dementia) 1520% (Frontotemporal dementia 10%)

3 Gross cerebral atrophy in AD

4 PET Imaging of Amyloid Deposits in Alzheimer s Disease vs Normal Controls PET imaging Pittsburgh Compound-B (PIB), can provide quantitative information on amyloid deposits in living subjects. Source: Klunk, et al. Ann Neurol 2004: 55:

5 Synaptic Pathology Alzheimer Normal Confocal images with anti-synaptophysin Robert Terry UCSD Reflected in FDG-PET

6 Synapse loss is crucial in the symptoms of dementia

7 Measuring synapses in human brain Major issues are they represent a small amount of total protein and that synapses may have cell bodies in different regions. Proteins synaptophysin is widely used as a general presynaptic marker; PSD95 as a postsynaptic marker. Specific markers of neurochemically defined synapses eg VGlut1 for cortical glutamate synapses. Postsynaptic markers include receptors such as NMDA.

8 Predicted energy use by grey matter Attwell and Iadecola TINS 25, 2002, Pages

9 VGlut1 in prefrontal cortex Kashani et al Neurobiol Aging 2007

10 Biphasic changes in VGlut1 in MCI and AD Bell, K. F. S. et al. J. Neurosci. 2007;27:

11 Synaptophysin and VGluT 1 in AD R C AD AD C AD AD A B C kda 36.5 A 58 C D 58 D Mean relative intensity B E G F H 1 Control AD * * * 0 Synaptophysin VGLUT1 VGLUT2 Kirvell et al,

12 Glutamate glutamine cycle in AD Glutamatergic pyramidal neurone Reduced VGluT Glutamate Glutamine NMDA receptor Glutamate/glutamine transporter LOWER PEAK Signal impaired Glutaminase Ca2+ HIGHER BACKGROUND High noise Postsynaptic pyramidal neurone Damaged reuptake protein, reduced function Astroglial cell ATP

13 Lewy body dementias DLB -accounts for 15-20% of all dementia in old age but only widely recognised since mid-1990 s. PDD dementia in PD (48% cross-sectional, 78% cumulative). Cortical LBs stained for ubiquitin Lewy neurites stained for -synuclein

14 Patterns of atrophy in AD and DLB vs control AD DLB Bilateral: insula, and thalamus. Right side: inf parietal lobule, sup temporal gyrus, inf temporal gyrus. Left side: red nucleus and middle occipital gyrus Beyer, M. K. et al. Neurology 2007;69:

15 Cases studied CONTROL DLB PDD AD Number of cases Age of death 80.4 ± ± ± ± 2.0 PMD (hours) 37.1 ± ± ± ± 5.4 Gender M/F (%) 58 / / / 47 31/69 Brain ph 6.47 ± ± ± ± 0.08 Detailed clinical information available for these cases: - Neuropathology report: Braak stage, CERAD, semi- quantitative scores of LBs, plaques and tangles - Cognitive and psychiatric tests: MMSE (mini-mental state examination) to assess cognitive decline Scoring of neuropsychiatric symptoms (frequency and intensity)

16 Mixed pathology in PDD/DLB PDD DLB Howlett et al, 2014

17 Correlates of cognitive decline in DLB/PDD n a-syn Ab NFT PSS BA BA BA BA Values are for the Spearman correlation coefficient between average MMSE decline/year and semi-quantitative score for 3 types of pathology (0-3) and PSS a simple summation of those scores. Those highlighted in red are significant (p<0.05) Model Standard Coeff Beta (Constant) NFT BA9 Ab BA21 a-syn BA21 (Constant) Ab BA21 a-syn BA t Sig Howlett et al, 2014

18 Pathophysiological changes at synapses in DLB. A D, Brain homogenates of six confirmed DLB cases (D1 D6) are compared with age-matched non-dementia controls (C1 C6). Kramer M L, Schulz-Schaeffer W J J. Neurosci. 2007;27: by Society for Neuroscience

19 Revealing previously undetectable, small granular α-synuclein aggregates with the PET blot. Kramer M L, Schulz-Schaeffer W J J. Neurosci. 2007;27:

20 Role of SNARE proteins in vesicle docking TETHERING DOCKING PRIMING VAMP2 SNAP-25 MUNC-18 FUSION COMPLEXIN SYNTAXIN 1 Steps in vesicle fusion including tethering, docking, priming and fusion at the presynaptic membrane. These events are regulated by calcium and calcium binding proteins through their interaction with SNARE proteins, mechanism not shown here.

21 Pathways and systems regulating Zn2+ homeostasis in neurons Sensi, Bush et al 2009 Nature Rev Neurosci

22 The role of synaptic Zn2+ in the regulation of postsynaptic targets and synaptic plasticity Sensi, Bush et al 2009 Nature Rev Neurosci

23 Diagnosis (1 6) (3 4) 1.2 (1 4) 0.0 A D LB (1 3) (4 6) 1.2 D 0.4 D *** A 1.2 (4 0) D LB B D Diagnosis (3 1) 0.0 (3 4) *** PD D 0.4 PSD95 (relative units) 0.8 co nt ro l( 23 ) (1 6) (4 4) *** PD D 0.8 PSD95 (relative units) D LB A D (3 1) 1.2 co nt ro l( 17 ) D LB A D (3 3) C PD D co nt ro l( 24 ) A PD D co nt ro l( 21 ) Cingulate cortex ZnT3 (relative units) Frontal cortex ZnT3 (relative units) ZnT3 & PSD95 by diagnosis *** * * Diagnosis * * Diagnosis Whitfield et al, 2014 Neurobiol Aging in press

24 Relationship of ZnT3 to cognition and pathology ** *** * ZnT3 (relative units) Classification of cognitive impairment Whitfield et al, 2014 Neurobiol Aging

25 Percentage of individuals according to depression score and diagnosis PDD 70 DLB 60 AD 50 Control absent mild Whitfield et al, 2014 AJGP in press moderate severe

26 ZnT3 concentration Zinc transporter 3 reduced in depression in dementia The ZnT3 concentration in frontal cortex is significantly different between depression groups 0 and 3. P=0.018 Severity of depression Whitfield et al, 2014 AJGP in press

27 Correlations with clinical features: depression Munc 18 BA * Munc 18 BA24 ** * 2 * 1.5 ** absent 0 0 intermittent mild N= 27 for absent N= 22 for intermittent mild N= 12 for intermittent significant N= 11 for persistent intermittent significant persistant N= 28 for absent N= 23 for intermittent mild N= 12 for intermittent significant N= 11 for persistent Level of Munc18 protein expression decreased with the severity of Depression Julie Vallortigara

28 α-synuclein by ELISA in Frontal cortex ### ### ** *** *** a-synuclein expression / LB pathology BA9 One-way ANOVA F(3,100)=67.85, p<0.001; Bonferroni post-hoc test One-way ANOVA F(3,96)=10.46, p<0.001; Bonferroni post-hoc test

29 Correlations between α-synuclein (ELISA) and ZnT3 concentrations in DLB &PDD Rs =0.341, p=0.008, n=59 Rs =0.451, p=0.001, n=51 Rs =0.418, p=0.001, n=64 No correlations with α-synuclein pathology scores in any region David Whitfield & Julie Vallortigara (unpublished data)

30 A model for inhibition of exocytosis by large α-syn oligomers Adapted from Choi et al., PNAS 2013.

31 Summary and conclusions Synaptic changes occur all various dementias Changes are different for each dementia and often different cerebral regions are affected. Synaptic changes may represent an early change and therefore provide an opportunity for early identification and novel treatment targets.

32 Acknowledgements London Clive Ballard, Tibor Hortobagyi, David Whitfield, Julie Vallortigara, David Howlett, Amani Alghamdi. Newcastle - Johannes Attems, Alan Thomas, John O Brien. Stavanger/Stockholm - Dag Aarsland, Jean-Ha Baek, Erika Bereczki, Mohammed Seed Ahmed.

33 Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease

More information

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration

More information

FDG-PET e parkinsonismi

FDG-PET e parkinsonismi Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism

More information

Dementia and Healthy Ageing : is the pathology any different?

Dementia and Healthy Ageing : is the pathology any different? Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association

More information

Neuro degenerative PET image from FDG, amyloid to Tau

Neuro degenerative PET image from FDG, amyloid to Tau Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging

More information

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5

More information

Parkinson e decadimento cognitivo. Stelvio Sestini

Parkinson e decadimento cognitivo. Stelvio Sestini Parkinson e decadimento cognitivo Stelvio Sestini Patients with PD can develop a spectrum of cognitive symptoms Heterogeneity of cognitive deficits The cognitive symptoms can evolve to dementia (Mov Disorder

More information

212 Index C-SB-13,

212 Index C-SB-13, Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration

More information

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine

More information

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal

More information

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16 The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei

More information

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends

More information

by Szabolcs Farkas MD Supervisor: László Csiba MD, PhD, DSc SHORT THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (PhD)

by Szabolcs Farkas MD Supervisor: László Csiba MD, PhD, DSc SHORT THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (PhD) SHORT THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (PhD) ALTERATION OF DOPAMINE AND ENDOCANNABINOID SYSTEM IN NEURODEGENERATIVE DISEASES: POSTMORTEM HUMAN AUTORADIOGRAPHIC STUDY ON PARKINSON S AND ALZHEIMER

More information

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer

More information

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation 1. Reflection of Mild Cognitive Impairment (MCI) and Dementias by Molecular Imaging, PET

More information

New life Collage of nursing Karachi

New life Collage of nursing Karachi New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology

More information

Update on functional brain imaging in Movement Disorders

Update on functional brain imaging in Movement Disorders Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF

More information

David Whitfield, Wolfson Centre for Age-Related Diseases, Guy s Campus, King s College

David Whitfield, Wolfson Centre for Age-Related Diseases, Guy s Campus, King s College Reduction of RPT6/S8 (a Proteasome component) and proteasome activity in the cortex is associated with cognitive impairment in Lewy body dementia. Amani Alghamdi PhD 1&2, Julie Vallortigara PhD 1, David

More information

Imaging biomarkers for Parkinson s disease

Imaging biomarkers for Parkinson s disease 3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 6 MDS-ES/EAN: Neuroimaging in movement disorders - Level 2 Imaging biomarkers for Parkinson

More information

CASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?

CASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories? CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.

More information

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits

More information

Imaging of Alzheimer s Disease: State of the Art

Imaging of Alzheimer s Disease: State of the Art July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression

More information

review of existing studies on ASL in dementia Marion Smits, MD PhD

review of existing studies on ASL in dementia Marion Smits, MD PhD review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam

More information

DEMENS MED LEWYLEGEMER OG PARKINSON DEMENS

DEMENS MED LEWYLEGEMER OG PARKINSON DEMENS DEMENS MED LEWYLEGEMER OG PARKINSON DEMENS Dag Årsland Regionalt senter for eldremedisin og samhndling (SEAM), Stavanger Dept of Old age psychiatry, Institute of Psychiatry, Psychology and Neuroscience,

More information

Differential Diagnosis of Alzheimer s Disease and Other Types of Dementia with Development of Neuroimaging Techniques (PET, SPECT, and MRI)

Differential Diagnosis of Alzheimer s Disease and Other Types of Dementia with Development of Neuroimaging Techniques (PET, SPECT, and MRI) www.jmscr.igmpublication.org Impact Factor 1.1147 ISSN (e)-2347-176x Differential Diagnosis of Alzheimer s Disease and Other Types of Dementia with Development of Neuroimaging Techniques (PET, SPECT, and

More information

QUIZ YOURSELF COLOSSAL NEURON ACTIVITY

QUIZ YOURSELF COLOSSAL NEURON ACTIVITY QUIZ YOURSELF What are the factors that produce the resting potential? How is an action potential initiated and what is the subsequent flow of ions during the action potential? 1 COLOSSAL NEURON ACTIVITY

More information

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018 Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been

More information

PET ligands and metabolic brain imaging Prof. Karl Herholz

PET ligands and metabolic brain imaging Prof. Karl Herholz PET ligands Karl Herholz, University of Manchester PET images in this lecture, unless indicated otherwise, are from Max-Planck-Institute for Neurological Research, Cologne, Germany 1 Positron-Emission-Tomography

More information

Emerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018

Emerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as

More information

Delirium & Dementia. Nicholas J. Silvestri, MD

Delirium & Dementia. Nicholas J. Silvestri, MD Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts

More information

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language

More information

Cerebral correlates of psychotic syndromes in neurodegenerative diseases

Cerebral correlates of psychotic syndromes in neurodegenerative diseases J. Cell. Mol. Med. Vol 16, No 5, 2012 pp. 995-1012 Cerebral correlates of psychotic syndromes in neurodegenerative diseases Kurt A. Jellinger Institute of Clinical Neurobiology, Vienna, Austria Received:

More information

Clinical Features and Treatment of Parkinson s Disease

Clinical Features and Treatment of Parkinson s Disease Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and

More information

King s Research Portal

King s Research Portal King s Research Portal DOI: 10.1016/j.neurobiolaging.2014.06.015 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA):, D. R.,

More information

Caring Sheet #11: Alzheimer s Disease:

Caring Sheet #11: Alzheimer s Disease: CARING SHEETS: Caring Sheet #11: Alzheimer s Disease: A Summary of Information and Intervention Suggestions with an Emphasis on Cognition By Shelly E. Weaverdyck, PhD Introduction This caring sheet focuses

More information

Assessing Cognition. Andreana Haley, Ph.D. Department of Psychology University of Texas at Austin

Assessing Cognition. Andreana Haley, Ph.D. Department of Psychology University of Texas at Austin Assessing Cognition Andreana Haley, Ph.D. Department of Psychology University of Texas at Austin Agenda Topic: Cognitive Aging Assessing Cognition Diagnosing Cognitive Impairment Dementia Diagnoses Symptoms

More information

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci. How to Diagnose Early (Prodromal) Lewy Body Dementia Ian McKeith MD, FRCPsych, F Med Sci. Parkinson s Disease Lewy Body Disease Time PD Dementia Lewy Body Dementias Dementia with Lewy Bodies (DLB) Diagnostic

More information

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME

More information

Mild cognitive impairment in Parkinson s disease: a distinct clinical entity?

Mild cognitive impairment in Parkinson s disease: a distinct clinical entity? Wen et al. Translational Neurodegeneration (2017) 6:24 DOI 10.1186/s40035-017-0094-4 REVIEW Mild cognitive impairment in Parkinson s disease: a distinct clinical entity? Ming-Ching Wen 1,2*, Ling Ling

More information

Alzheimer s Disease without Dementia

Alzheimer s Disease without Dementia Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and

More information

Neuropathology of old-age dementia

Neuropathology of old-age dementia Australian Association of Gerontology Adelaide, September 22 2015 Neuropathology of old-age dementia University of Cambridge, Institute of Public Health Suvi R. K. Hokkanen, MD MPH srkh2@medschl.cam.ac.uk

More information

ORIGINAL CONTRIBUTION. Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease

ORIGINAL CONTRIBUTION. Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease ORIGINAL CONTRIBUTION Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease Vahram Haroutunian, PhD; Daniel P. Perl, MD; Dushyant P. Purohit,

More information

Overview of neurological changes in Alzheimer s disease. Eric Karran

Overview of neurological changes in Alzheimer s disease. Eric Karran Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,

More information

UNIT 5 REVIEW GUIDE - NERVOUS SYSTEM 1) State the 3 functions of the nervous system. 1) 2) 3)

UNIT 5 REVIEW GUIDE - NERVOUS SYSTEM 1) State the 3 functions of the nervous system. 1) 2) 3) UNIT 5 REVIEW GUIDE - NERVOUS SYSTEM State the 3 functions of the nervous system. Briefly describe the general function(s) of each of the following neuron types: a) SENSORY NEURONS: b) INTERNEURONS: c)

More information

Lecture 42: Final Review. Martin Wessendorf, Ph.D.

Lecture 42: Final Review. Martin Wessendorf, Ph.D. Lecture 42: Final Review Martin Wessendorf, Ph.D. Lecture 33 cortex Heilbronner 5 lobes of the cortex Lateral view (left side) Mid-saggital view (right side) Cellular organization of cortex White matter

More information

A Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong

A Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong Outline The pathogenesis of Late life cognitive impairment A framework

More information

The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease

The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,

More information

Behavioral Task Performance

Behavioral Task Performance Zacks 1 Supplementary content for: Functional Reorganization of Spatial Transformations After a Parietal Lesion Jeffrey M. Zacks, PhD *, Pascale Michelon, PhD *, Jean M. Vettel, BA *, and Jeffrey G. Ojemann,

More information

The Aging Brain The Aging Brain

The Aging Brain The Aging Brain The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu

More information

Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease

Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease John C. Morris, MD Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology Disclosure Statement

More information

Neurons! John A. White Dept. of Bioengineering

Neurons! John A. White Dept. of Bioengineering Neurons! John A. White Dept. of Bioengineering john.white@utah.edu What makes neurons different from cardiomyocytes? Morphological polarity Transport systems Shape and function of action potentials Neuronal

More information

Il ruolo di nuove tecniche di imaging per la diagnosi precoce di demenza

Il ruolo di nuove tecniche di imaging per la diagnosi precoce di demenza Parma, 23 maggio 2017 Il ruolo di nuove tecniche di imaging per la diagnosi precoce di demenza Livia Ruffini SC Medicina Nucleare Azienda Ospedaliero-Universitaria di Parma PET AND SPECT STUDIES OF THE

More information

Investigating molecular mechanisms of progression of Parkinson s Disease in human brain

Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Murray ; C.E., Pressey ; S.N., Heywood 2 ; W.E., Hargreaves 3 ; I.P., Neergheen 3 ; V., Wauters ; S., Palkovits 4

More information

Functional Development of Neuronal Networks in Culture -An in vitro Assay System of Developing Brain for Endocrine Disruptors

Functional Development of Neuronal Networks in Culture -An in vitro Assay System of Developing Brain for Endocrine Disruptors Functional Development of Neuronal Networks in Culture -An in vitro Assay System of Developing Brain for Endocrine Disruptors Masahiro Kawahara and Yoichiro Kuroda Tokyo Metropolitan Institute for Neuroscience

More information

The Cerebral Cortex and Higher Intellectual Functions

The Cerebral Cortex and Higher Intellectual Functions The Cerebral Cortex and Higher Intellectual Functions The Cerebral cortex consists of 2 cerebral hemisphere and each hemisphere consists of 5 lobes (frontal, parietal,temporal,occipital,insular lobe which

More information

Neuroinflammation in preclinical AD: in vivo evidence

Neuroinflammation in preclinical AD: in vivo evidence Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of

More information

FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS

FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology

More information

The Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD

The Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD The Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD Division of Cognitive and Behavioral Neurology, Brigham and Women s Hospital Co-Director of the Center

More information

DEMENTIA IN PARKINSON`S DISEASE. DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD

DEMENTIA IN PARKINSON`S DISEASE. DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD DEMENTIA IN PARKINSON`S DISEASE DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD DEMENTIA IN PD The concept of Non Motor Symptoms in PD Dementia in Parkinson`s

More information

Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition

Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition Ann Nucl Med (2015) 29:78 83 DOI 10.1007/s12149-014-0911-0 ORIGINAL ARTICLE Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition Kazunari Ishii Chisa Hosokawa

More information

Altered proteins in the aging brain

Altered proteins in the aging brain Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1182 Altered proteins in the aging brain ADILA ELOBEID ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2016 ISSN 1651-6206 ISBN

More information

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia. Psychiatric disorders of the elderly OLD AGE PSYCHIATRY Dementia Depression Delusional disorder/late onset schizophrenia Delirium Dementia definition LOCALISATION OF CEREBRAL FUNCTION Impairment of multiple

More information

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,

More information

Supplementary Material S3 Further Seed Regions

Supplementary Material S3 Further Seed Regions Supplementary Material S3 Further Seed Regions Figure I. Changes in connectivity with the right anterior insular cortex. (A) wake > mild sedation, showing a reduction in connectivity between the anterior

More information

Dementia spectrum disorders: lessons learnt from decades with PET research

Dementia spectrum disorders: lessons learnt from decades with PET research Journal of Neural Transmission (2019) 126:233 251 https://doi.org/10.1007/s00702-019-01975-4 NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - REVIEW ARTICLE Dementia spectrum disorders: lessons learnt

More information

Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.

Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease

More information

Dementia and Alzheimer s disease

Dementia and Alzheimer s disease Since 1960 Medicine Korat โรงพยาบาลมหาราชนครราชส มา Dementia and Alzheimer s disease Concise Reviews PAWUT MEKAWICHAI MD DEPARTMENT of MEDICINE MAHARAT NAKHON RATCHASIMA HOSPITAL 1 Prevalence Increase

More information

NIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2010 March 18.

NIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2010 March 18. NIH Public Access Author Manuscript Published in final edited form as: Arch Neurol. 2009 May ; 66(5): 646 651. doi:10.1001/archneurol.2009.46. Cortical α7 Nicotinic Acetylcholine Receptor and β-amyloid

More information

Synaptic Transmission: Ionic and Metabotropic

Synaptic Transmission: Ionic and Metabotropic Synaptic Transmission: Ionic and Metabotropic D. Purves et al. Neuroscience (Sinauer Assoc.) Chapters 5, 6, 7. C. Koch. Biophysics of Computation (Oxford) Chapter 4. J.G. Nicholls et al. From Neuron to

More information

NACC Neuropathology (NP) Diagnosis Coding Guidebook

NACC Neuropathology (NP) Diagnosis Coding Guidebook Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu

More information

Kurt A. Jellinger. 2 nd Int. Conference BrainNet Europe, Munich, Dec , 2008 NAC A30P A53T ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH

Kurt A. Jellinger. 2 nd Int. Conference BrainNet Europe, Munich, Dec , 2008 NAC A30P A53T ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH 2 nd Int. Conference BrainNet Europe, Munich, Dec. 10-12, 2008 NH 3 1 NAC 125 133 136 A30P A53T 125 140 ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH 29 71 82 125 129 (Src) (GRK5, CK-1 & CK-2) Kurt A.

More information

King s Research Portal

King s Research Portal King s Research Portal DOI: 10.3233/JAD-160946 Link to publication record in King's Research Portal Citation for published version (APA): Alghamdi, A., Vallortigara, J., Howlett, D. R., Broadstock, M.,

More information

Brain imaging for the diagnosis of people with suspected dementia

Brain imaging for the diagnosis of people with suspected dementia Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis

More information

TUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019

TUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019 KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019

More information

NIH Public Access Author Manuscript Semin Neurol. Author manuscript; available in PMC 2014 November 14.

NIH Public Access Author Manuscript Semin Neurol. Author manuscript; available in PMC 2014 November 14. NIH Public Access Author Manuscript Published in final edited form as: Semin Neurol. 2013 September ; 33(4): 386 416. doi:10.1055/s-0033-1359312. Neuroimaging Biomarkers of Neurodegenerative Diseases and

More information

How Synapses Integrate Information and Change

How Synapses Integrate Information and Change How Synapses Integrate Information and Change Rachel Stewart class of 2016 http://neuroscience.uth.tmc.edu/s1/chapter06.html http://neuroscience.uth.tmc.edu/s1/chapter07.html Chris Cohan, Ph.D. Dept. of

More information

2/14/2013. The Pathogenesis of Parkinson s Disease. February, inherited forms of PD. Autosomal Recessive Parkinson s Disease

2/14/2013. The Pathogenesis of Parkinson s Disease. February, inherited forms of PD. Autosomal Recessive Parkinson s Disease inherited forms of PD The Pathogenesis of Parkinson s Disease February, 2013 PARK1 dominant α-synuclein presynaptic protein PARK2 recessive parkin E3 ubiquitin ligase PARK3 dominant 2p13? PARK4 dominant

More information

USE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013

USE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013 Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER

More information

Dementia. Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Dementia. Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine Dementia Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine What is Dementia? Dementia is a general term referring to a decline in cognitive/mental functioning; this decline

More information

Moving Targets: An Update on Diagnosing Dementia in the Clinic

Moving Targets: An Update on Diagnosing Dementia in the Clinic Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures

More information

Assessing and Managing the Patient with Cognitive Decline

Assessing and Managing the Patient with Cognitive Decline Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor

More information

TUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019

TUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019 KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019

More information

ADNI and DIAN Neuropathology Core

ADNI and DIAN Neuropathology Core NI and DIAN Neuropathology Core Update October 14, 2016 Nigel Cairns, PhD, FRCPath Knight RC Neuropathology Core Leader NI Participants Autopsied per Funding Period Autopsy rates for NI1, NI GO, and NI2

More information

! slow, progressive, permanent loss of neurologic function.

! slow, progressive, permanent loss of neurologic function. UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation

More information

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event

More information

The Marmoset Monkey as Model for Neurological Disorders

The Marmoset Monkey as Model for Neurological Disorders The Marmoset Monkey as Model for Neurological Disorders Jan Langermans and Ingrid Philippens From Laboratory to Clinic Disease models neuroscience: Parkinson, Sleep, Stress, Alzheimer, MS MS Models: rhmog

More information

The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease

The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease AIBL: Two site collaborative study Study is conducted at two sites: Perth

More information

Supplementary Figure 1. SybII and Ceb are sorted to distinct vesicle populations in astrocytes. Nature Neuroscience: doi: /nn.

Supplementary Figure 1. SybII and Ceb are sorted to distinct vesicle populations in astrocytes. Nature Neuroscience: doi: /nn. Supplementary Figure 1 SybII and Ceb are sorted to distinct vesicle populations in astrocytes. (a) Exemplary images for cultured astrocytes co-immunolabeled with SybII and Ceb antibodies. SybII accumulates

More information

Inverse Relationship Between Cerebrovascular Lesions and Severity of Lewy Body Pathology in Patients With Lewy Body Diseases

Inverse Relationship Between Cerebrovascular Lesions and Severity of Lewy Body Pathology in Patients With Lewy Body Diseases J Neuropathol Exp Neurol Copyright Ó 2010 by the American Association of Neuropathologists, Inc. Vol. 69, No. 5 May 2010 pp. 442Y448 ORIGINAL ARTICLE Inverse Relationship Between Cerebrovascular Lesions

More information

Autopsy Committee Sample Autopsy Case. Alzheimer Disease. Authors Ashley Thorburn, MD. Joseph E. Parisi, MD Autopsy Committee

Autopsy Committee Sample Autopsy Case. Alzheimer Disease. Authors Ashley Thorburn, MD. Joseph E. Parisi, MD Autopsy Committee Autopsy Committee Sample Autopsy Case Alzheimer Disease Authors Ashley Thorburn, MD Joseph E. Parisi, MD Autopsy Committee Clinical Summary: A 75-year-old man presented to his primary care physician with

More information

Neurotransmitter Functioning In Major Depressive Disorder

Neurotransmitter Functioning In Major Depressive Disorder Neurotransmitter Functioning In Major Depressive Disorder Otsuka Pharmaceutical Development & Commercialization, Inc. 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD January

More information

Opinion 18 December 2013

Opinion 18 December 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 AMYVID 800 MBq/ml solution for injection 10 ml vial (CIP: 34009 585 065 4 3) 15 ml vial (CIP: 34009

More information

TUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL)

TUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL) KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 28, 2017

More information

Form D1: Clinician Diagnosis

Form D1: Clinician Diagnosis Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.

More information

Facility IBA 18/9 Cyclotron Accelerates p and d. Facility GMP Grade Clean Room Automated Dispenser Synthera Rig FDG 07/11/2014

Facility IBA 18/9 Cyclotron Accelerates p and d. Facility GMP Grade Clean Room Automated Dispenser Synthera Rig FDG 07/11/2014 Dr Chris Marshall Director Introduction to PET Positron Emission Tomography Positron is anti matter equivalent of the electron Isotopes that are proton rich can decay by emission of a positron Positron

More information

ORIGINAL CONTRIBUTION. Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease

ORIGINAL CONTRIBUTION. Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease ORIGINAL CONTRIBUTION Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease Vahram Haroutunian, PhD; Dushyant P. Purohit, MD; Daniel P. Perl, MD; Deborah Marin, MD; Khalid

More information

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe A. J. Harding, 1 G. A. Broe 1 and G. M. Halliday 1 Brain (2002), 125, 391±403 1 Prince of Wales Medical Research Institute

More information

Synaptic plasticity. Activity-dependent changes in synaptic strength. Changes in innervation patterns. New synapses or deterioration of synapses.

Synaptic plasticity. Activity-dependent changes in synaptic strength. Changes in innervation patterns. New synapses or deterioration of synapses. Synaptic plasticity Activity-dependent changes in synaptic strength. Changes in innervation patterns. New synapses or deterioration of synapses. Repair/changes in the nervous system after damage. MRC Centre

More information

Biomarkers for Alzheimer s disease

Biomarkers for Alzheimer s disease Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer

More information